HAMBURG, Germany ― Once-weekly tirzepatide (Mounjaro, Lilly) added to insulin glargine resulted in greater reductions in A1c along with more weight loss and less hypoglycemia compared with prandial ...

Please provide your email address to receive an email when new articles are posted on . Rosenstock and colleagues analyzed data from 247 adults with type 2 diabetes with an HbA1c between 7% and 9.5% ...

The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) on December 16 announced that the U.S. Food and Drug Administration (FDA) granted approval for Basaglar ...

The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on December 15 that BASAGLAR (insulin glargine injection 100 units/mL) is available by prescription in ...

A phase 2 clinical trial found safety and efficacy comparable to daily insulin There’s good news for Type 2 diabetes patients who hope to relax their daily insulin use. The Endocrine Society on Sunday ...

Please provide your email address to receive an email when new articles are posted on . Among adults with type 2 diabetes, biosimilar insulin was noninferior to insulin glargine for lowering HbA1c, ...

Weekly insulin shots can help control both Type 1 and Type 2 diabetes as well as daily injections do, a pair of clinical trials have found. Photo by Adobe Stock/HealthDay News Weekly insulin shots can ...

"Sustained glycemic control with once-weekly injections of insulin icodec would lead to better patient acceptance and treatment satisfaction," the authors wrote. The comparator group included ...

Mylan Pharmaceuticals has recalled some insulin-glargine injection pens because they may be missing labels. According to an announcement with the U.S. Food and Drug Administration, the lack of a label ...

WASHINGTON -- The U.S. government has cleared the way for the first medical device that enables automated insulin dosing for people with type 2 diabetes. The plastic pod, called the Omnipod 5 ...

Weekly insulin shots can help control both Type 1 and Type 2 diabetes as well as daily injections do, a pair of clinical trials have found. A new class of insulin called efsitora alfa has been ...